Semaglutide use in people with obesity and type 2 diabetes from real‐world utilization data: An analysis of the All of US Program
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Aim: To analyse data from the All of Us Research Program to evaluate the real‐world application and long‐term effectiveness of semaglutide in treating type 2 diabetes and obesity patients in a large population. Materials and Methods: We identified patients prescribed semaglutide and analysed differences in route of administration and the time on semaglutide. For individuals diagnosed with obesity, we measured changes in body mass index (BMI) and weight from baseline, while measured changes in HbA1c for those patients with type 2 diabetes. We also examined the occurrence of newly diagnosed common adverse events from taking semaglutide. Results: For 3739 semaglutide patients, those on injectable semaglutide (3364 patients) averaged 301.54 days on the medication, with 20.36% having no end date, while those on oral semaglutide (435 patients) averaged 172.48 days, with 24.60% having no end date. We found average decreases of 1.54 kg/m 2 in BMI, 4.65 kg in weight and 0.75% in HbA1c for semaglutide users. The decreases were larger in participants taking injectable formulation, probably because of higher starting values. Over time, improvements in these outcomes diminished, but the values remained significantly lower than baseline levels. Approximately only 1.0% of patients reported newly diagnosed common adverse events. Conclusions: Consistent with clinical trial findings, this real‐world data analysis showed that semaglutide was well tolerated and that, for a large population, it effectively reduced BMI, body weight and HbA1c, albeit to smaller magnitudes than observed in clinical trials. These findings provide valuable insights into real‐world experience and the long‐term effectiveness of semaglutide.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The “All of Us” Research Program
The All of Us Research Program Investigators (2019) · New England Journal of Medicine · doi:10.1056/nejmsr1809937 · Cited by 2,440
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Sorli, C., Harashima, S.-I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30013-x · Cited by 745 · cited 1×
“…the clinical trials leading to US Food and Drug Administration approval (Pivotal Trials) associated with semaglu-tide (NCT02054897 for Ozempic and NCT02906930 for Rybelsus) for people with type 2 diabetes, 11 – 14 our evaluation also showed decreases in HbA1c, but to a lesser extent than in trials.”
Aroda, V. R., Rosenstock, J., Terauchi, Y., Altuntas, Y., Lalic, N. M., Morales Villegas, E. C., Jeppesen, O. K., Christiansen, E., Hertz, C. L., Haluzík, M., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0749 · Cited by 493 · cited 1×
“…the clinical trials leading to US Food and Drug Administration approval (Pivotal Trials) associated with semaglu-tide (NCT02054897 for Ozempic and NCT02906930 for Rybelsus) for people with type 2 diabetes, 11 – 14 our evaluation also showed decreases in HbA1c, but to a lesser extent than in trials.”
Smits, M. M., & Van Raalte, D. H. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.645563 · Cited by 332
Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide
Hathaway, J. T., Shah, M. P., Hathaway, D. B., Zekavat, S. M., Krasniqi, D., Gittinger, J. W., Cestari, D., Mallery, R., Abbasi, B., Bouffard, M., et al. (2024) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2024.2296 · Cited by 318
Aroda, V. R., Aberle, J., Bardtrum, L., Christiansen, E., Knop, F. K., Gabery, S., Pedersen, S. D., & Buse, J. B. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01127-3 · Cited by 126
Chao, A. M., Tronieri, J. S., Amaro, A., & Wadden, T. A. (2022) · Drug Design, Development and Therapy · doi:10.2147/dddt.s365416 · Cited by 58 · cited 1×
“In assessing the effects of semaglutide on individuals with obesity, we only considered BMI and weight.”
Ruseva, A., Michalak, W., Zhao, Z., Fabricatore, A., Hartaigh, B. Ó., & Umashanker, D. (2024) · Obesity Science & Practice · doi:10.1002/osp4.737 · Cited by 40
Obesity: Avoid using BMI alone when evaluating patients, say US doctors’ leaders
Tanne, J. H. (2023) · BMJ · doi:10.1136/bmj.p1400 · Cited by 28
Cited by
Thomsen, R. W., Mailhac, A., Løhde, J. B., & Pottegård, A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16364 · Cited by 207
Obesity Treatment With Bariatric Surgery vs GLP-1 Receptor Agonists
Barrett, T. S., Hafermann, J. O., Richards, S., LeJeune, K., & Eid, G. M. (2025) · JAMA Surgery · doi:10.1001/jamasurg.2025.3590 · Cited by 87
Unexpected effects of semaglutide on skeletal muscle mass and force-generating capacity in mice
Karasawa, T., Choi, R. H., Meza, C. A., Rout, S., Drummond, M. J., Chaix, A., & Funai, K. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2025.07.004 · Cited by 29
Treat to target in weight management with semaglutide: Real‐world evidence from an eHealth clinic
Seier, S., Stamp‐Larsen, K., Jensen, S. B. K., Torekov, S. S., & Gudbergsen, H. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.70096 · Cited by 15
“20,22,23,35 However, real-world studies based on adults specifically on higher semaglutide doses indicated for obesity (1.7 or 2.4 mg/week) show weight loss of 10% – 12% after six months 18 of treatment, which is similar to the 12.2% weight loss obtained on average after 6 months in the present…”
InfluentialAnatriello, A., Liguori, V., Cagnotta, C., Pentella, C., Scavone, C., Capuano, A., & Rinaldi, B. (2026) · Frontiers in pharmacology · doi:10.3389/fphar.2026.1808359 · Cited by 3
“Based on the quality assessment, 18 out of 28 studies were classified as being of good quality, achieving three or four stars for the selection domain, two stars for the comparability domain, and three stars for the outcome domain/exposure domain; four studies were classified as being of fair quality, achieving two st…”
Influential
Metadata
- Authors
- Mayer, C. S., & Fontelo, P.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2024-09-09
- Volume
- 26
- Issue
- 11
- Pages
- 4989-4995
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W4402371567
- Cited by
- 12
- References
- 10
- FWCI
- 3.26
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Semaglutide use in people with obesity and type 2 diabetes from real‐world utilization data: An analysis of the All of US Program. https://app.cochat.ai/papers/10.1111/dom.15911
- The paper
- Mayer, C. S., & Fontelo, P. (2024). Semaglutide use in people with obesity and type 2 diabetes from real‐world utilization data: An analysis of the All of US Program. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15911
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.